Share-based Payment Arrangement, Expense of STANDARD BIOTOOLS INC. from 30 Jun 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
STANDARD BIOTOOLS INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2011 to 30 Sep 2025.
  • STANDARD BIOTOOLS INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $7,536,000, a 62% increase year-over-year.
  • STANDARD BIOTOOLS INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $33,979,000, a 47% increase year-over-year.
  • STANDARD BIOTOOLS INC. annual Share-based Payment Arrangement, Expense for 2024 was $31,732,000, a 142% increase from 2023.
  • STANDARD BIOTOOLS INC. annual Share-based Payment Arrangement, Expense for 2023 was $13,123,000, a 12% decline from 2022.
  • STANDARD BIOTOOLS INC. annual Share-based Payment Arrangement, Expense for 2022 was $14,880,000, a 7.6% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

STANDARD BIOTOOLS INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $33,979,000 $7,536,000 +$2,887,000 +62% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $31,092,000 $5,372,000 +$1,962,000 +58% 01 Apr 2025 30 Jun 2025 10-Q 15 Aug 2025 2025 Q2
Q1 2025 $29,130,000 $9,009,000 -$2,602,000 -22% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $31,732,000 $12,062,000 +$8,587,000 +247% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $23,145,000 $4,649,000 +$1,263,000 +37% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $21,882,000 $3,410,000 +$296,000 +9.5% 01 Apr 2024 30 Jun 2024 10-Q 15 Aug 2025 2025 Q2
Q1 2024 $21,586,000 $11,611,000 +$8,463,000 +269% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $13,123,000 $3,475,000 +$1,794,000 +107% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $11,329,000 $3,386,000 -$1,108,000 -25% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $12,437,000 $3,114,000 -$1,549,000 -33% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $13,986,000 $3,148,000 -$894,000 -22% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q3
Q4 2022 $14,880,000 $1,681,000 -$2,682,000 -61% 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2025 2024 FY
Q3 2022 $17,562,000 $4,494,000 +$174,000 +4% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $17,388,000 $4,663,000 +$922,000 +25% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $16,466,000 $4,042,000 +$365,000 +9.9% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $16,101,000 $4,363,000 +$269,000 +6.6% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q3 2021 $15,832,000 $4,320,000 -$37,000 -0.85% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $15,869,000 $3,741,000 +$107,000 +2.9% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $15,762,000 $3,677,000 +$1,311,000 +55% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $14,451,000 $4,094,000 +$993,000 +32% 01 Oct 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 $13,458,000 $4,357,000 +$1,328,000 +44% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $12,130,000 $3,634,000 +$642,000 +21% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $11,488,000 $2,366,000 +$95,000 +4.2% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $11,393,000 $3,101,000 -$1,865,000 -38% 01 Oct 2019 31 Dec 2019 10-K 08 Mar 2022 2021 FY
Q3 2019 $13,258,000 $3,029,000 +$726,000 +32% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $12,532,000 $2,992,000 +$985,000 +49% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $11,547,000 $2,271,000 +$524,000 +30% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $11,023,000 $4,966,000 +$2,874,000 +137% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $8,149,000 $2,303,000 +$3,000 +0.13% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 $8,146,000 $2,007,000 -$293,000 -13% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $8,439,000 $1,747,000 -$653,000 -27% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $9,092,000 $2,092,000 -$766,000 -27% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q3 2017 $9,858,000 $2,300,000 -$1,300,000 -36% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $11,158,000 $2,300,000 -$1,400,000 -38% 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $12,558,000 $2,400,000 -$1,300,000 -35% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $13,858,000 $2,858,000 01 Oct 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
Q3 2016 $3,600,000 -$500,000 -12% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $3,700,000 -$900,000 -20% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $3,700,000 -$400,000 -9.8% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q3 2015 $4,100,000 -$1,900,000 -32% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $4,600,000 -$1,300,000 -22% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $4,100,000 +$700,000 +21% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q3 2014 $6,000,000 +$4,300,000 +253% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $5,900,000 +$4,200,000 +247% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2
Q1 2014 $3,400,000 +$2,100,000 +162% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q3 2013 $1,700,000 +$700,000 +70% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $1,700,000 +$600,000 +55% 01 Apr 2013 30 Jun 2013 10-Q 04 Aug 2014 2014 Q2
Q1 2013 $1,300,000 +$400,000 +44% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
Q3 2012 $1,000,000 +$300,000 +43% 01 Jul 2012 30 Sep 2012 10-Q 07 Nov 2013 2013 Q3
Q2 2012 $1,100,000 +$600,000 +120% 01 Apr 2012 30 Jun 2012 10-Q 07 Aug 2013 2013 Q2
Q1 2012 $900,000 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1
Q3 2011 $700,000 01 Jul 2011 30 Sep 2011 10-Q 09 Nov 2012 2012 Q3
Q2 2011 $500,000 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012 2012 Q2

STANDARD BIOTOOLS INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $31,732,000 +$18,609,000 +142% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $13,123,000 -$1,757,000 -12% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $14,880,000 -$1,221,000 -7.6% 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2025 2024 FY
2021 $16,101,000 +$1,650,000 +11% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
2020 $14,451,000 +$3,058,000 +27% 01 Jan 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
2019 $11,393,000 +$370,000 +3.4% 01 Jan 2019 31 Dec 2019 10-K 08 Mar 2022 2021 FY
2018 $11,023,000 +$1,931,000 +21% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $9,092,000 -$4,766,000 -34% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $13,858,000 01 Jan 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.